Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. Shares traded 13% higher ahead of the morning bell at $42.
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
Nektar Therapeutics (NKTR) stock jumps on positive mid-stage trial data for its experimental drug targeting atopic dermatitis. Read more here.
An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...
Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...
Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine with anti-fibrotic effects in lungs Compelling results compared ...
New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on ...
Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...
Evommune, Inc. EVMN shares jumped Tuesday following the announcement of positive top-line results from its Phase 2a trial evaluating EVO301 for treating moderate-to-severe atopic dermatitis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results